Compare ASTH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | NBTX |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2015 | 2018 |
| Metric | ASTH | NBTX |
|---|---|---|
| Price | $38.77 | $35.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $34.86 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 487.5K | 49.3K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $519,907,752.00 | N/A |
| Revenue This Year | $27.38 | $58.17 |
| Revenue Next Year | $10.78 | N/A |
| P/E Ratio | $135.07 | ★ N/A |
| Revenue Growth | ★ 45.90 | N/A |
| 52 Week Low | $18.08 | $4.57 |
| 52 Week High | $40.13 | $57.14 |
| Indicator | ASTH | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 46.06 |
| Support Level | $36.47 | $30.15 |
| Resistance Level | $40.03 | $41.89 |
| Average True Range (ATR) | 1.48 | 2.54 |
| MACD | -0.17 | -0.17 |
| Stochastic Oscillator | 76.78 | 55.10 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.